StageZero Life Sciences Ltd. (TSX: SZLS) (OTC: GNWSF) Featured in Virtual Coverage of the Spring Investor Summit 2020
StageZero Life Sciences (TSX: SZLS) (OTC: GNWSF) is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, the company’s next-generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on the company’s proven and proprietary Sentinel Principle Technology Platform, which has been validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the company…







